Because of their unique capacity to move and execute complicated tasks at tiny sizes, medical nanorobotics hold a lot of potential for improving medical diagnosis and therapy. Nonetheless, the field's greatest hurdle is its effective translation into broad patient usage. We critically examine the cutting-edge of existing in vivo methods and analyse current and future commercialization prospects. Despite the fact that no "killer application" has yet to emerge to drive quick commercialization, recent technical achievements have resulted in the effective in vivo functioning of medical nanorobots. We also discuss how standardised nanorobotics report summaries is critical not just for improving research quality but also for reducing investment risk in their eventual commercialization.
